AMINOGLYCOSIDE INDUCED OTOTOXICITY IN PATIENTS WITH CYSTIC-FIBROSIS

被引：35

作者：

MULHERIN, D ^{[1
]}

FAHY, J ^{[1
]}

GRANT, W ^{[1
]}

KEOGAN, M ^{[1
]}

KAVANAGH, B ^{[1
]}

FITZGERALD, M ^{[1
]}

机构：

[1] NATL UNIV IRELAND UNIV COLL DUBLIN,DUBLIN 4,IRELAND

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 1991年 / 160卷 / 06期

关键词：

D O I：

10.1007/BF02961666

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The improved survival of cystic fibrosis (CF) patients is partly due to intensive treatment for their chronic infections. Treatment usually includes intravenous and nebulised aminoglycoside antibiotics and they receive a large cumulative dose of these antibiotics over their lifetime. There is little information in the literature on the prevalence of ototoxicity due to aminoglycoside in these patients. We performed pure tone auditometry on 43 CF patients aged 14-42 years. Seven (16%) had bilateral sensorineural hearing loss (SNHL) for high frequency sounds, consistent with aminoglycoside induced ototoxicity. However, only 2 of these patients had documented toxic serum levels in the past. The identification of bilateral SNHL in one in six adult CF patients is a cause for concern. It may be that the high cumulative dose of aminoglycosides received by these patients may be causing inner ear injury in the absence of specific episodes of toxic serum levels.

引用

页码：173 / 175

页数：3

共 18 条

[1]

De Arce M., Mulherin D., McWillia P., Lawler M., FitzGerald M.X., Humphries P., Frequency of deletion 508 among Irish cystic fibrosis patients, Hum. Gen., 85, pp. 403-404, (1990)

[2]

Nevin G.B., Nevin N.C., Redmond A.O., Prevalence and survival of patients with cystic fibrosis in Northern Ireland, 1961-1971, Ulster Med. J., 52, pp. 153-156, (1983)

[3]

Gibson L.E., Cooke R.E., A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilising pilocarpine by iontophoresis, Pediatrics, 23, pp. 545-549, (1959)

[4]

Phelan P.D., Hey E., Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-1980, Arch. Dis. Child, 59, pp. 71-73, (1984)

[5]

Corey M.L., Longitudinal studies in cystic fibrosis, In: Perspectives in Cystic Fibrosis, pp. 246-255, (1980)

[6]

Neilsen O.H., Schiotz P.O., Cystic fibrosis in Denmark in the period 1945-1981. Evaluation of centralised treatment, Acta Paediatr. Scand, 301, pp. 107-119, (1982)

[7]

Penketh A.R.L., Wise A., Mea M.B., Hodson M.E., Batten J.C., Cystic fibrosis in adolescents and adults, Thorax, 42, pp. 526-532, (1987)

[8]

Kea G.L., Hilman B.C., Wilson J.T., Dosing implications of altered gentamicin desposition in patients with cystic fibrosis, J. Pediatr., 100, pp. 312-218, (1982)

[9]

Kelly H.B., Menendez R., Leland F., Murphy S., Pharmacokinetics of tobramycin in cystic fibrosis, J. Pediatr., 100, pp. 318-321, (1982)

[10]

Buring J.E., Evans D.A., Mayrent S.L., Rosner B., Colton T., Hennekens C.H., Randomised trials of arninoglycoside antibiotics: quantitative overview, Rev. Infect Dis., 10, pp. 951-957, (1988)

← 1 2 →